Inhibition of human liver aldehyde oxidase: Implications for potential drug-drug interactions

Drug Metabolism and Disposition

Volumn 39, Issue 12, 2011, Pages 2381-2386

  Barr, John T ^a   Jones, Jeffrey P ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 DICHLOROPHENOLINDOPHENOL; 6 CHLOROQUINAZOLINONE; ALDEHYDE OXIDASE; CHLORPROMAZINE; CLOZAPINE; DOMPERIDONE; ESTRADIOL; ETHINYLESTRADIOL; MENADIONE; QUINAZOLINONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG POTENCY; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; IC 50; LIVER CYTOSOL; OXIDATION; PREDICTION; PRIORITY JOURNAL;

ALDEHYDE OXIDASE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; HUMANS; LIVER;

EID: 81855217400     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.041806     Document Type: Article

References (27)

1. Alfaro JF, Joswig-Jones CA, Ouyang W, Nichols J, Crouch GJ, and Jones JP (2009) Purification and mechanism of human aldehyde oxidase expressed in Escherichia coli. Drug Metab Dispos 37:2393-2398.
2. Bachmann KA (2006) Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug drug interactions: pitfalls, progress and promise. Curr Drug Metab 7:1-14.
3. Beedham C, Miceli JJ, and Obach RS (2003) Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol 23:229-232. (Pubitemid 36807789)
4. Bibi Z (2008) Role of cytochrome P450 in drug interactions. Nutr Metab (Lond) 5:27.
5. Blanchard N, Richert L, Coassolo P, and Lavé T (2004) Qualitative and quantitative assessment of drug-drug interaction potential in man, based on Ki, IC50 and inhibitor concentration. Curr Drug Metab 5:147-156. (Pubitemid 38515244)
6. Brandänge S and Lindblom L (1979) The enzyme "aldehyde oxidase" is an iminium oxidase. Reaction with nicotine Δ1′ (5′) iminium ion. Biochem Biophys Res Commun 91:991-996. (Pubitemid 10145373)
7. Brunton LL, Gilman A, and Goodman LS (2006) Goodman & Gilman's the Pharmacological Basis of Therapeutics, 12 ed, McGraw-Hill, New York.
8. Chiba M, Jin L, Neway W, Vacca JP, Tata JR, Chapman K, and Lin JH (2001) P450 interaction with HIV protease inhibitors: relationship between metabolic stability, inhibitory potency, and P450 binding spectra. Drug Metab Dispos 29:1-3. (Pubitemid 32041672)
9. Clarke SE, Harrell AW, and Chenery RJ (1995) Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver. Drug Metab Dispos 23:251-254.
10. Cook PB and Cleland WW (2007) Enzyme Kinetics and Mechanism, Garland Science, New York.
11. Dahl SG and Strandjord RE (1977) Pharmacokinetics of chlorpromazine after single and chronic dosage. Clin Pharmacol Ther 21:437.
12. Garattini E and Terao M (2011) Increasing recognition of the importance of aldehyde oxidase in drug development and discovery. Drug Metab Rev 43:374-386.
13. Ito K, Brown HS, and Houston JB (2004) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473-486. (Pubitemid 38519653)
14. Jordan CG, Rashidi MR, Laljee H, Clarke SE, Brown JE, and Beedham C (1999) Aldehyde oxidase-catalysed oxidation of methotrexate in the liver of guinea-pig, rabbit and man. J Pharm Pharmacol 51:411-418. (Pubitemid 29248317)
15. Lake BG, Ball SE, Kao J, Renwick AB, Price RJ, and Scatina JA (2002) Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. Xenobiotica 32:835-847. (Pubitemid 35155519)
16. Obach RS (2004) Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos 32:89-97.
17. Obach RS, Huynh P, Allen MC, and Beedham C (2004) Human liver aldehyde oxidase: inhibition by 239 drugs. J Clin Pharmacol 44:7-19. (Pubitemid 38005089)
18. Ortiz de Montellano PR (2005) Cytochrome P450: Structure, Mechanism, and Biochemistry, 3rd ed, Plenum, New York.
19. Panoutsopoulos GI and Beedham C (2004) Enzymatic oxidation of phthalazine with guinea pig liver aldehyde oxidase and liver slices: inhibition by isovanillin. Acta Biochim Pol 51:943-951. (Pubitemid 40192542)
20. Peng CC, Pearson JT, Rock DA, Joswig-Jones CA, and Jones JP (2010) The effects of type II binding on metabolic stability and binding affinity in cytochrome P450 CYP3A4. Arch Biochem Biophys 497:68-81.
21. Piwowarska J, Radowicki S, and Pachecka J (2010) Simultaneous determination of eight estrogens and their metabolites in serum using liquid chromatography with electrochemical detection. Talanta 81:275-280.
22. Pryde DC, Dalvie D, Hu Q, Jones P, Obach RS, and Tran TD (2010) Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem 53:8441-8460.
23. Rajagopalan KV and Handler P (1964) Hepatic aldehyde oxidase. 3. The substrate-binding site.J Biol Chem 239:2027-2035.
24. Rashidi MR, Smith JA, Clarke SE, and Beedham C (1997) In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Drug Metab Dispos 25:805-813. (Pubitemid 27318599)
25. Tucker GT, Houston JB, and Huang SM (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - toward a consensus. Pharm Res 18:1071-1080. (Pubitemid 32900389)
26. Westhoff CL, Torgal AH, Mayeda ER, Pike MC, and Stanczyk FZ (2010) Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. Contraception 81:474-480.
27. Whittlesea CM and Gorrod W (1993) The enzymology of the in-vitro oxidation of prolintane to oxoprolintane. J Clin Pharm Ther 18:357-364. (Pubitemid 23313621)